(Q51346081)

English

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.

scientific article published in June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

type 2 diabetes

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Yi Min Cui

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Xiao Hui Guo

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Dong Mei Zhang

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Lai San Tham

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Cheng Cai Tang

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Kenneth Mace

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Helle Linnebjerg

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

publication date

1 June 2013

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Journal of diabetes

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

127-135

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Prevalence of diabetes among men and women in China

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12020

21 January 2018

Identifiers

10.1111/1753-0407.12020

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23332026

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51346081&oldid=2143791089"